CA3013047A1 - Use of histone deacetylase inhibitors for enhancing immunotherapies - Google Patents

Use of histone deacetylase inhibitors for enhancing immunotherapies Download PDF

Info

Publication number
CA3013047A1
CA3013047A1 CA3013047A CA3013047A CA3013047A1 CA 3013047 A1 CA3013047 A1 CA 3013047A1 CA 3013047 A CA3013047 A CA 3013047A CA 3013047 A CA3013047 A CA 3013047A CA 3013047 A1 CA3013047 A1 CA 3013047A1
Authority
CA
Canada
Prior art keywords
entinostat
phenyl
methyl
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3013047A
Other languages
English (en)
French (fr)
Inventor
Roberto PILI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of CA3013047A1 publication Critical patent/CA3013047A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3013047A 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies Abandoned CA3013047A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288121P 2016-01-28 2016-01-28
US62/288,121 2016-01-28
PCT/US2017/015389 WO2017132536A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Publications (1)

Publication Number Publication Date
CA3013047A1 true CA3013047A1 (en) 2017-08-03

Family

ID=58010402

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013047A Abandoned CA3013047A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Country Status (13)

Country Link
US (1) US10813919B2 (https=)
EP (1) EP3407913A1 (https=)
JP (1) JP2019503386A (https=)
KR (1) KR20180104122A (https=)
CN (1) CN108883179A (https=)
AU (1) AU2017211383A1 (https=)
BR (1) BR112018015291A2 (https=)
CA (1) CA3013047A1 (https=)
IL (1) IL260765A (https=)
MX (1) MX2018009247A (https=)
RU (1) RU2018130831A (https=)
WO (1) WO2017132536A1 (https=)
ZA (1) ZA201805066B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
CA3066053A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
TR201900059A2 (tr) * 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
WO2019140296A1 (en) * 2018-01-12 2019-07-18 Viracta Therapeutics, Inc. Epigenetic modifiers for use in cellular immunotherapy
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
CN112569360A (zh) * 2019-09-30 2021-03-30 中国医学科学院药物研究所 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用
CA3227993A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
WO2024231293A1 (en) * 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer
US20240382463A1 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition Comprising HDAC Inhibitor and Immune Checkpoin Inhibitor and Methods For Using the Same
US12553903B2 (en) 2023-06-01 2026-02-17 Cg Pharmaceuticals, Inc Ivaltinostat combination therapy for treating pancreatic cancer
WO2025155922A1 (en) * 2024-01-19 2025-07-24 The Trustees Of Indiana University Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
JP2018508593A (ja) * 2015-03-20 2018-03-29 シンダックス ファーマシューティカルズ，インコーポレイティド がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
US20180250320A1 (en) 2015-08-26 2018-09-06 The Johns Hopkins University Compositions and methods for treating solid tumors
AU2016318136B2 (en) * 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy

Also Published As

Publication number Publication date
US20190030011A1 (en) 2019-01-31
WO2017132536A1 (en) 2017-08-03
JP2019503386A (ja) 2019-02-07
EP3407913A1 (en) 2018-12-05
RU2018130831A3 (https=) 2020-04-23
BR112018015291A2 (pt) 2018-12-18
MX2018009247A (es) 2019-03-11
KR20180104122A (ko) 2018-09-19
CN108883179A (zh) 2018-11-23
IL260765A (en) 2018-10-31
ZA201805066B (en) 2019-05-29
US10813919B2 (en) 2020-10-27
AU2017211383A1 (en) 2018-08-16
RU2018130831A (ru) 2020-03-02

Similar Documents

Publication Publication Date Title
US10813919B2 (en) Use of histone deacetylase inhibitors for enhancing immunotherapies
Devasia et al. Bispecific antibodies in the treatment of multiple myeloma
Shen et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models
Iclozan et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
Mokarizadeh et al. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling
Wainwright et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors
Beres et al. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease
Ridnour et al. NOS inhibition modulates immune polarization and improves radiation-induced tumor growth delay
Li et al. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth
Panek et al. Local application of autologous platelet-rich fibrin patch (PRF-P) suppresses regulatory T cell recruitment in a murine glioma model
CN114286681A (zh) Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂
JP2018522045A (ja) Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節
Wachowska et al. Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy
Shi et al. Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer
Wang et al. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice
JP7233220B2 (ja) Ｈｄａｃ阻害剤とｂｅｔ阻害剤の使用方法及びその薬学的組み合わせ
CA2819829A1 (en) Compositions and methods for treating foxp3+ treg related diseases
Hu et al. PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model
KR101968184B1 (ko) 저산소 조건을 이용한 면역세포의 증식 배양 방법
US20230172984A1 (en) CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF iNKT CELLS
ES2789574T3 (es) Modulación de la activación del inflamasoma de células supresoras derivadas de mieloides para el tratamiento de GvHD o tumor
Liu et al. Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity
CN104138391B (zh) 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用
CN120936370A (zh) 用于使用肿瘤治疗电场和杀伤细胞治疗癌症的组合物、系统和方法
KR102538055B1 (ko) 사이토카인 폭풍 조절제 스크리닝 방법

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220727